cholestyramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
727 11041-12-6

Description:

MoleculeDescription

Synonyms:

  • colestyramine
  • cholestyramine
  • cholestyramine chloride
  • colestyramin
  • Molecular weight: 1162
  • Formula: C68H97Cl5N5
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
14 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Aug. 3, 1973 FDA BRISTOL MYERS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 214.91 13.22 506 16116 938684 89673141
Product taste abnormal 104.85 13.22 32 16590 2428 90609397
Product physical consistency issue 94.30 13.22 24 16598 930 90610895
Product solubility abnormal 78.98 13.22 21 16601 968 90610857
Frequent bowel movements 60.75 13.22 63 16559 56872 90554953
Colitis 60.01 13.22 69 16553 69873 90541952
Product residue present 58.83 13.22 24 16598 4267 90607558
Abdominal pain 51.03 13.22 174 16448 395547 90216278
Glossodynia 47.17 13.22 3 16619 321776 90290049
Bowel movement irregularity 46.23 13.22 23 16599 6491 90605334
Abdominal distension 45.46 13.22 84 16538 130517 90481308
Drug ineffective for unapproved indication 44.60 13.22 58 16564 66586 90545239
Systemic lupus erythematosus 43.74 13.22 7 16615 361889 90249936
Laparotomy 43.22 13.22 11 16611 426 90611399
Bulimia nervosa 41.45 13.22 11 16611 503 90611322
Intestinal obstruction 41.26 13.22 42 16580 37089 90574736
Contraindicated product administered 39.11 13.22 6 16616 320133 90291692
Wound 38.61 13.22 5 16617 302975 90308850
Faecal calprotectin increased 37.23 13.22 17 16605 3970 90607855
Clostridium difficile infection 36.68 13.22 39 16583 36206 90575619
Gastrointestinal wall thickening 36.46 13.22 14 16608 2123 90609702
Product use complaint 35.96 13.22 16 16606 3517 90608308
Rheumatoid arthritis 34.05 13.22 12 16610 362602 90249223
Intestinal stenosis 33.88 13.22 15 16607 3259 90608566
Intestinal anastomosis 30.97 13.22 10 16612 912 90610913
Flatulence 30.84 13.22 38 16584 41329 90570496
Helicobacter infection 30.76 13.22 3 16619 226847 90384978
Sacroiliitis 30.25 13.22 15 16607 4204 90607621
Constipation 29.91 13.22 116 16506 280279 90331546
Toxicity to various agents 29.76 13.22 8 16614 287838 90323987
Cholangitis sclerosing 29.01 13.22 12 16610 2209 90609616
Intestinal resection 28.97 13.22 13 16609 2914 90608911
Intestinal fibrosis 28.71 13.22 7 16615 227 90611598
Mesenteric vein thrombosis 28.38 13.22 10 16612 1191 90610634
Rash macular 27.88 13.22 31 16591 30249 90581576
Ileal stenosis 27.74 13.22 12 16610 2466 90609359
Bile acid malabsorption 27.10 13.22 7 16615 288 90611537
Anal incontinence 27.02 13.22 23 16599 16207 90595618
Folliculitis 26.94 13.22 3 16619 204350 90407475
Therapeutic product effect decreased 26.37 13.22 9 16613 277562 90334263
Proctalgia 25.74 13.22 17 16605 8181 90603644
Post procedural diarrhoea 25.39 13.22 7 16615 370 90611455
Small intestinal obstruction 25.39 13.22 25 16597 21209 90590616
Cerebral venous sinus thrombosis 24.95 13.22 11 16611 2365 90609460
Functional gastrointestinal disorder 24.92 13.22 14 16608 5048 90606777
Blood alkaline phosphatase increased 24.90 13.22 37 16585 48042 90563783
Ophthalmoplegia 24.72 13.22 10 16612 1739 90610086
Type 2 diabetes mellitus 24.38 13.22 4 16618 203240 90408585
Terminal ileitis 24.26 13.22 9 16613 1241 90610584
Foreign body in throat 23.75 13.22 7 16615 471 90611354
Off label use 23.33 13.22 306 16316 1101946 89509879
Impaired healing 23.29 13.22 7 16615 234192 90377633
Nephrolithiasis 22.92 13.22 36 16586 49049 90562776
Product odour abnormal 22.26 13.22 9 16613 1562 90610263
Gastroenteritis 22.03 13.22 27 16595 29202 90582623
Ill-defined disorder 21.39 13.22 4 16618 184887 90426938
Jaundice 21.28 13.22 28 16594 32489 90579336
Stomatitis 21.21 13.22 12 16610 274686 90337139
Suprapubic pain 20.93 13.22 7 16615 713 90611112
Drug level decreased 20.89 13.22 16 16606 9714 90602111
Arthropathy 20.68 13.22 22 16600 366220 90245605
Serum ferritin increased 20.07 13.22 14 16608 7367 90604458
Pleural rub 19.10 13.22 4 16618 64 90611761
Anal fissure 18.96 13.22 12 16610 5373 90606452
Enterocutaneous fistula 18.87 13.22 8 16614 1566 90610259
Colectomy 18.47 13.22 10 16612 3357 90608468
Cystitis 18.46 13.22 39 16583 66679 90545146
Infusion related reaction 18.45 13.22 30 16592 416750 90195075
Retching 18.30 13.22 20 16602 19139 90592686
Vascular device infection 18.00 13.22 16 16606 11936 90599889
Dehydration 17.98 13.22 77 16545 194370 90417455
Lower respiratory tract infection 17.89 13.22 12 16610 250647 90361178
Plasma cell myeloma 17.77 13.22 29 16593 40799 90571026
Therapeutic reaction time decreased 17.69 13.22 10 16612 3648 90608177
Crohn's disease 17.56 13.22 11 16611 4840 90606985
Wheezing 17.53 13.22 11 16611 238069 90373756
Sarcoma 17.51 13.22 6 16616 658 90611167
Clostridium difficile colitis 17.48 13.22 23 16599 26683 90585142
Cholecystitis infective 17.45 13.22 8 16614 1884 90609941
Fibromyalgia 17.43 13.22 8 16614 206261 90405564
Colitis microscopic 16.93 13.22 15 16607 11144 90600681
Intestinal anastomosis complication 16.90 13.22 5 16617 341 90611484
Joint swelling 16.53 13.22 43 16579 503257 90108568
Urinary tract infection 16.40 13.22 104 16518 305528 90306297
Cholelithiasis 16.07 13.22 32 16590 52474 90559351
Alanine aminotransferase increased 16.05 13.22 53 16569 118285 90493540
Swelling 16.02 13.22 33 16589 419025 90192800
Hepatic steatosis 15.75 13.22 26 16596 36919 90574906
Aspartate aminotransferase increased 15.70 13.22 48 16574 102889 90508936
Weight decreased 15.54 13.22 121 16501 379789 90232036
Cholestatic liver injury 14.73 13.22 9 16613 3788 90608037
Remission not achieved 14.27 13.22 4 16618 225 90611600
Ileostomy 14.16 13.22 7 16615 1947 90609878
Tinnitus 14.08 13.22 27 16595 43075 90568750
Choking 14.08 13.22 14 16608 12019 90599806
Klebsiella infection 13.97 13.22 13 16609 10284 90601541
Thyrotoxic crisis 13.91 13.22 6 16616 1225 90610600
Discomfort 13.84 13.22 18 16604 274317 90337508
Blister 13.64 13.22 16 16606 254982 90356843
Diarrhoea haemorrhagic 13.58 13.22 13 16609 10650 90601175
Thyroidectomy 13.51 13.22 6 16616 1313 90610512
Benign vulval neoplasm 13.51 13.22 3 16619 64 90611761
Trance 13.51 13.22 3 16619 64 90611761
Gait inability 13.47 13.22 5 16617 146451 90465374
Neuropathy peripheral 13.25 13.22 55 16567 136915 90474910

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 91.86 16.09 262 8983 460587 42151503
Alveolar lung disease 80.77 16.09 19 9226 443 42611647
Pulmonary interstitial emphysema syndrome 77.04 16.09 19 9226 544 42611546
Diffuse alveolar damage 52.01 16.09 20 9225 2572 42609518
Intestinal intraepithelial lymphocytes increased 48.95 16.09 11 9234 208 42611882
Cryptitis 45.84 16.09 11 9234 280 42611810
Drug ineffective 43.39 16.09 258 8987 629939 41982151
Microvillous inclusion disease 42.51 16.09 10 9235 233 42611857
Nerve degeneration 38.84 16.09 9 9236 196 42611894
Intestinal obstruction 38.79 16.09 38 9207 27120 42584970
Apoptosis 38.07 16.09 11 9234 582 42611508
Product taste abnormal 37.70 16.09 13 9232 1226 42610864
Eosinophilic pneumonia 36.96 16.09 19 9226 4855 42607235
Probiotic therapy 35.41 16.09 8 9237 155 42611935
Faecal calprotectin increased 32.29 16.09 15 9230 3079 42609011
Abdominal rigidity 31.13 16.09 12 9233 1553 42610537
Hyperammonaemia 30.95 16.09 20 9225 7846 42604244
Hemivertebra 30.78 16.09 7 9238 140 42611950
Dehydration 29.32 16.09 82 9163 141685 42470405
Colitis microscopic 29.04 16.09 14 9231 3119 42608971
Vascular device infection 27.72 16.09 17 9228 6093 42605997
Gastric polyps 26.63 16.09 11 9234 1704 42610386
Small intestinal obstruction 26.48 16.09 25 9220 17036 42595054
Arthralgia 26.43 16.09 101 9144 205137 42406953
Erosive duodenitis 26.18 16.09 11 9234 1778 42610312
Transaminases abnormal 25.46 16.09 7 9238 309 42611781
Frequent bowel movements 25.20 16.09 27 9218 21380 42590710
Product solubility abnormal 25.03 16.09 8 9237 596 42611494
Biopsy 24.93 16.09 7 9238 334 42611756
Gastrointestinal anastomotic stenosis 24.77 16.09 5 9240 55 42612035
Abdominal pain 24.74 16.09 94 9151 190377 42421713
Hepatic enzyme abnormal 24.58 16.09 13 9232 3519 42608571
Fistula 23.71 16.09 17 9228 7895 42604195
Hepatic encephalopathy 23.46 16.09 23 9222 16419 42595671
Thyrotoxic crisis 22.50 16.09 8 9237 826 42611264
Enterocolonic fistula 22.08 16.09 5 9240 98 42611992
Escherichia urinary tract infection 22.02 16.09 13 9232 4350 42607740
Oesophageal atresia 21.89 16.09 7 9238 522 42611568
Renal mass 21.81 16.09 10 9235 1992 42610098
Glomerular filtration rate decreased 21.72 16.09 22 9223 16329 42595761
Renal neoplasm 21.36 16.09 9 9236 1466 42610624
Generalised oedema 21.04 16.09 21 9224 15315 42596775
Flatulence 20.08 16.09 26 9219 25126 42586964
Abdominal adhesions 19.92 16.09 9 9236 1733 42610357
Bacterial diarrhoea 19.28 16.09 5 9240 176 42611914
Intestinal stenosis 18.61 16.09 10 9235 2794 42609296
Toxicity to various agents 18.03 16.09 14 9231 229122 42382968
Bone density decreased 17.89 16.09 9 9236 2197 42609893
Lymphocyte count increased 17.65 16.09 11 9234 4053 42608037
Inappropriate schedule of product administration 17.43 16.09 53 9192 95849 42516241
Ileus 17.21 16.09 21 9224 19118 42592972
Rectal haemorrhage 17.08 16.09 35 9210 49571 42562519
Duodenitis 16.79 16.09 12 9233 5544 42606546
Hernia 16.75 16.09 16 9229 11057 42601033
Short-bowel syndrome 16.26 16.09 5 9240 328 42611762

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 160.25 13.24 513 19686 1138992 109430108
Pulmonary interstitial emphysema syndrome 79.88 13.24 19 20180 556 110568544
Alveolar lung disease 75.66 13.24 19 20180 700 110568400
Product solubility abnormal 66.62 13.24 19 20180 1143 110567957
Intestinal obstruction 66.40 13.24 64 20135 53163 110515937
Faecal calprotectin increased 63.96 13.24 29 20170 6690 110562410
Off label use 58.58 13.24 470 19729 1499715 109069385
Product physical consistency issue 58.34 13.24 18 20181 1422 110567678
Abdominal pain 53.51 13.24 210 19989 512779 110056321
Intestinal intraepithelial lymphocytes increased 49.69 13.24 11 20188 232 110568868
Diffuse alveolar damage 46.71 13.24 20 20179 4027 110565073
Vascular device infection 46.62 13.24 32 20167 16480 110552620
Small intestinal obstruction 46.47 13.24 42 20157 32171 110536929
Bowel movement irregularity 45.63 13.24 24 20175 7636 110561464
Cryptitis 44.43 13.24 11 20188 382 110568718
Drug ineffective 44.19 13.24 447 19752 1520093 109049007
Microvillous inclusion disease 42.85 13.24 10 20189 269 110568831
Drug ineffective for unapproved indication 40.94 13.24 70 20129 102768 110466332
Intestinal resection 40.72 13.24 18 20181 3911 110565189
Intestinal stenosis 40.65 13.24 19 20180 4696 110564404
Abdominal distension 40.51 13.24 95 20104 175008 110394092
Toxicity to various agents 38.31 13.24 20 20179 480535 110088565
Dehydration 38.12 13.24 125 20074 279386 110289714
Apoptosis 37.74 13.24 11 20188 715 110568385
Product taste abnormal 37.54 13.24 15 20184 2537 110566563
Nerve degeneration 37.40 13.24 9 20190 277 110568823
Thyrotoxic crisis 37.15 13.24 14 20185 2026 110567074
Probiotic therapy 36.03 13.24 8 20191 171 110568929
Frequent bowel movements 35.82 13.24 54 20145 71336 110497764
Eosinophilic pneumonia 35.69 13.24 20 20179 7207 110561893
Product residue present 34.35 13.24 16 20183 3925 110565175
Clostridium difficile infection 32.90 13.24 44 20155 52085 110517015
Therapeutic reaction time decreased 32.76 13.24 17 20182 5262 110563838
Anal fissure 32.35 13.24 21 20178 9860 110559240
Colitis 32.30 13.24 63 20136 102260 110466840
Product use complaint 31.79 13.24 15 20184 3788 110565312
Colitis microscopic 31.00 13.24 23 20176 13371 110555729
Abdominal adhesions 30.40 13.24 15 20184 4175 110564925
Cerebrovascular accident 30.23 13.24 87 20112 181197 110387903
Glossodynia 29.77 13.24 3 20196 222001 110347099
Flatulence 28.40 13.24 41 20158 52108 110516992
Blood pressure increased 27.87 13.24 107 20092 258266 110310834
Laparotomy 27.18 13.24 8 20191 538 110568562
Wound 27.12 13.24 5 20194 234432 110334668
Systemic lupus erythematosus 26.25 13.24 7 20192 254331 110314769
Rheumatoid arthritis 26.12 13.24 11 20188 299602 110269498
Inappropriate schedule of product administration 25.91 13.24 89 20110 203548 110365552
Psoriatic arthropathy 25.52 13.24 3 20196 196758 110372342
Erosive duodenitis 25.38 13.24 11 20188 2280 110566820
Enterocolonic fistula 25.21 13.24 6 20193 176 110568924
Hepatic encephalopathy 24.52 13.24 28 20171 28228 110540872
Gastrointestinal anastomotic stenosis 24.26 13.24 5 20194 74 110569026
Hyperammonaemia 24.04 13.24 20 20179 13712 110555388
Arthralgia 23.84 13.24 232 19967 779400 109789700
Gastric polyps 23.84 13.24 14 20185 5509 110563591
Cholangitis sclerosing 23.57 13.24 12 20187 3570 110565530
Contraindicated product administered 23.50 13.24 8 20191 248259 110320841
Mesenteric vein thrombosis 23.49 13.24 10 20189 1985 110567115
Gastrointestinal wall thickening 23.44 13.24 12 20187 3611 110565489
Abdominal rigidity 23.26 13.24 12 20187 3668 110565432
Intestinal anastomosis 22.90 13.24 8 20191 933 110568167
Functional gastrointestinal disorder 22.66 13.24 14 20185 6035 110563065
Poor venous access 22.48 13.24 25 20174 24497 110544603
Jaundice 21.85 13.24 39 20160 59197 110509903
Duodenitis 21.75 13.24 16 20183 9180 110559920
Terminal ileitis 21.70 13.24 9 20190 1675 110567425
Colectomy 21.31 13.24 12 20187 4366 110564734
Nephrolithiasis 21.17 13.24 41 20158 66171 110502929
Biopsy 20.75 13.24 7 20192 735 110568365
Drug level decreased 20.71 13.24 21 20178 18527 110550573
Folliculitis 20.67 13.24 3 20196 167650 110401450
Drug level above therapeutic 20.54 13.24 17 20182 11571 110557529
Lymphocyte count increased 20.43 13.24 14 20185 7189 110561911
Stomatitis 20.42 13.24 12 20187 270230 110298870
Blood alkaline phosphatase increased 20.37 13.24 42 20157 70893 110498207
Type 2 diabetes mellitus 20.03 13.24 4 20195 177228 110391872
Bile acid malabsorption 19.52 13.24 6 20193 468 110568632
Anal incontinence 19.46 13.24 22 20177 21942 110547158
Completed suicide 19.42 13.24 10 20189 242371 110326729
Fibromyalgia 19.02 13.24 4 20195 170905 110398195
Pleural rub 18.94 13.24 4 20195 67 110569033
Product odour abnormal 18.85 13.24 8 20191 1575 110567525
Transaminases abnormal 18.79 13.24 7 20192 981 110568119
Ileal stenosis 18.78 13.24 10 20189 3260 110565840
Arthropathy 18.76 13.24 15 20184 287507 110281593
Renal neoplasm 18.62 13.24 9 20190 2397 110566703
Proctalgia 18.60 13.24 17 20182 13205 110555895
Foreign body in throat 18.29 13.24 7 20192 1056 110568044
Serum ferritin increased 18.18 13.24 16 20183 11831 110557269
Ophthalmoplegia 18.01 13.24 10 20189 3540 110565560
Ileus 17.97 13.24 25 20174 30704 110538396
Hepatic steatosis 17.81 13.24 32 20167 48799 110520301
Renal mass 17.79 13.24 10 20189 3625 110565475
Ill-defined disorder 16.79 13.24 4 20195 156849 110412251
Drug interaction 16.78 13.24 42 20157 500141 110068959
Enteritis 16.65 13.24 19 20180 19137 110549963
Plasma cell myeloma 16.61 13.24 36 20163 62900 110506200
Bacterial diarrhoea 16.59 13.24 5 20194 365 110568735
Fistula 16.50 13.24 17 20182 15282 110553818
Intestinal anastomosis complication 16.17 13.24 5 20194 398 110568702
Weight decreased 16.14 13.24 143 20056 467914 110101186
Drug hypersensitivity 16.13 13.24 37 20162 454053 110115047
Glomerular filtration rate decreased 16.10 13.24 23 20176 28933 110540167
Impaired healing 15.93 13.24 8 20191 196709 110372391
Wheezing 15.80 13.24 14 20185 255216 110313884
Myopathy 15.64 13.24 21 20178 24939 110544161
Swelling 15.61 13.24 25 20174 351016 110218084
Myalgia 15.57 13.24 81 20118 222300 110346800
Generalised oedema 15.08 13.24 23 20176 30681 110538419
Heart rate decreased 15.04 13.24 41 20158 82715 110486385
Sarcoma 15.04 13.24 6 20193 1011 110568089
Rectal haemorrhage 14.91 13.24 52 20147 119781 110449319
Choking 14.88 13.24 16 20183 15094 110554006
Duodenal polyp 14.87 13.24 5 20194 520 110568580
Stoma complication 14.85 13.24 6 20193 1045 110568055
Hernia 14.73 13.24 18 20181 19482 110549618
Hepatic fibrosis 14.65 13.24 12 20187 8054 110561046
Infusion site extravasation 14.52 13.24 14 20185 11620 110557480
Therapeutic product effect decreased 14.42 13.24 14 20185 244302 110324798
Metastasis 14.39 13.24 12 20187 8255 110560845
Escherichia urinary tract infection 14.00 13.24 16 20183 16146 110552954
Gastroenteritis 13.61 13.24 25 20174 38775 110530325
Lung disorder 13.59 13.24 8 20191 180039 110389061
Vanishing bile duct syndrome 13.59 13.24 8 20191 3160 110565940
Benign vulval neoplasm 13.52 13.24 3 20196 64 110569036
Haematochezia 13.40 13.24 49 20150 115475 110453625

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C10AC01 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Bile acid sequestrants
FDA MoA N0000175365 Bile-acid Binding Activity
FDA EPC N0000180292 Bile Acid Sequestrant
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:35821 anticholesteremic drug
CHEBI has role CHEBI:50671 antithyroid drug
CHEBI has role CHEBI:231911 renoprotective agent

Related Drugs by ATC class:

C10AC Bile acid sequestrants 3 drugs
colesevelamcolestipolcolextran

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypercholesterolemia indication 13644009
Hyperlipidemia indication 55822004 DOID:1168
Biliary Obstruction with Pruritus indication
Poisoning by digitalis glycoside off-label use 12876009
Chronic diarrhea off-label use 236071009
Classical phenylketonuria contraindication 7573000
Constipation contraindication 14760008 DOID:2089
Hypovolemia contraindication 28560003
Blood coagulation disorder contraindication 64779008 DOID:1247
Hemorrhoids contraindication 70153002 DOID:9746
Kidney disease contraindication 90708001 DOID:557
Calculus in biliary tract contraindication 266474003
Complete Biliary Obstruction contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4018811 VUID
N0000147114 NUI
D02690 KEGG_DRUG
2447 RXNORM
CHEBI:749501 CHEBI
CHEMBL1201625 ChEMBL_ID
1005 INN_ID
DB01432 DRUGBANK_ID
4B33BGI082 UNII
4435 MMSL
6264 MMSL
d00193 MMSL
001216 NDDF
387408001 SNOMEDCT_US
72824008 SNOMEDCT_US
C0008402 UMLSCUI
4018811 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Prevalite HUMAN PRESCRIPTION DRUG LABEL 1 0245-0036 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
CHOLESTYRAMINE HUMAN PRESCRIPTION DRUG LABEL 1 24658-266 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
CHOLESTYRAMINE LIGHT HUMAN PRESCRIPTION DRUG LABEL 1 24658-270 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
CHOLESTYRAMINE LIGHT HUMAN PRESCRIPTION DRUG LABEL 1 24658-271 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
Cholestyramine Human Prescription Drug Label 1 27241-134 POWDER, FOR SUSPENSION 4 g ORAL ANDA 20 sections
Cholestyramine Human Prescription Drug Label 1 33342-293 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
Cholestyramine Human Prescription Drug Label 1 33342-293 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
Cholestyramine Human Prescription Drug Label 1 33342-319 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 42571-508 POWDER, FOR SUSPENSION 4 g ORAL ANDA 20 sections
CHOLESTYRAMINE HUMAN PRESCRIPTION DRUG LABEL 1 42806-265 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
CHOLESTYRAMINE HUMAN PRESCRIPTION DRUG LABEL 1 42806-266 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
CHOLESTYRAMINE HUMAN PRESCRIPTION DRUG LABEL 1 42806-267 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
CHOLESTYRAMINE LIGHT HUMAN PRESCRIPTION DRUG LABEL 1 42806-269 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
CHOLESTYRAMINE LIGHT HUMAN PRESCRIPTION DRUG LABEL 1 42806-270 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
CHOLESTYRAMINE LIGHT HUMAN PRESCRIPTION DRUG LABEL 1 42806-271 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 49884-465 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 49884-466 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
QUESTRAN HUMAN PRESCRIPTION DRUG LABEL 1 49884-936 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
QUESTRAN HUMAN PRESCRIPTION DRUG LABEL 1 49884-937 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 50090-3415 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
CHOLESTYRAMINE HUMAN PRESCRIPTION DRUG LABEL 1 50090-3845 POWDER, FOR SUSPENSION 4 g ORAL ANDA 12 sections
Cholestyramine Light HUMAN PRESCRIPTION DRUG LABEL 1 51224-009 POWDER, FOR SUSPENSION 4 g ORAL ANDA 23 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 51224-011 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 54868-4812 POWDER, FOR SUSPENSION 4 g ORAL ANDA 14 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 54868-5526 POWDER, FOR SUSPENSION 4 g ORAL ANDA 14 sections
Cholestyramine for Oral Suspension HUMAN PRESCRIPTION DRUG LABEL 1 62135-008 POWDER 4 g ORAL ANDA 13 sections
Cholestyramine for Oral Suspension HUMAN PRESCRIPTION DRUG LABEL 1 62135-937 POWDER 4 g ORAL ANDA 13 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 63629-2162 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 63629-2164 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
cholestyramine powder for suspension HUMAN PRESCRIPTION DRUG LABEL 1 63629-9196 POWDER, FOR SUSPENSION 4 g ORAL ANDA 19 sections